Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Viking Therapeutics, Inc. VKTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$103.00
+190.6%

Viking Therapeutics, Inc. (VKTX) is a Biotechnology company in the Healthcare sector, currently trading at $35.45. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is VKTX = $103 (+190.6% upside).

Valuation: VKTX trades at a trailing Price-to-Earnings (P/E) of -10.7 (S&P 500 average ~25).

Net income is $360M (loss), growing at -94.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $137,000 against $639M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 9.33 (strong liquidity). Debt-to-assets is 0%. Total assets: $716M.

Analyst outlook: 22 / 23 analysts rate VKTX as buy (96%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$103.00
▲ 190.55% Upside
Average Price Target
Based on 23 Wall Street analysts offering 12-month price targets for Viking Therapeutics, Inc., the average price target is $103.00, with a high forecast of $107.00, and a low forecast of $99.00.
Highest Price Target
$107.00
Average Price Target
$103.00
Lowest Price Target
$99.00

VKTX SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VKTX

✓
VALUE Pass
100/100
VKTX trades at a trailing Price-to-Earnings (P/E) of -10.7 (S&P 500 average ~25). Forward PEG -1.35 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.21. Analyst consensus target is $103, implying +190.6% from the current price $35. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
VKTX: +0%/yr revenue is, -94.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet VKTX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 9.33 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
VKTX: Gross margin is 0% (+0 pp trend), $4B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 22 / 23 analysts rate VKTX as buy (96%). Analyst consensus target is $103 (+190.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range18.92-43.15
Volume1.66M
Avg Volume (30D)2.69M
Market Cap$4.1B
Beta (1Y)0.82
Share Statistics
EPS (TTM)-3.19
Shares Outstanding$112.67M
IPO Date2015-04-28
Employees45
CEOBrian Lian
Financial Highlights & Ratios
Gross Profit$-431K
EBITDA$-393.34M
Net Income$-359.64M
Operating Income$-393.34M
Total Cash$705.74M
Total Debt$137K
Net Debt$-165.67M
Total Assets$715.73M
Price / Earnings (P/E)-11.1
Analyst Forecast
1Y Price Target$103.00
Target High$107.00
Target Low$99.00
Upside+190.6%
Rating ConsensusBuy
Analysts Covering23
Buy 96% Hold 4% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS92686J1060

Price Chart

Track all markets on TradingView
VKTX
Viking Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
18.92 52WK RANGE 43.15

People Also View

MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$518.58
-1.22%
 AXSM
AXSM
Axsome Therapeutics, Inc.
$184.18
+0.07%
 IMGN
IMGN
ImmunoGen, Inc.
$31.24
+0.02%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 PTCT
PTCT
PTC Therapeutics, Inc.
$73.57
+0.77%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 SRPT
SRPT
Sarepta Therapeutics, Inc.
$21.73
-1.90%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message